Charles River’s portfolio of syngeneic models have been well-characterized in their responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1, anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.

The majority of our models have also undergone whole exome sequencing (WES) to enhance your model selection, giving you the ability to choose based on mutation status in addition to sensitivity immune checkpoint inhibitors.

Fill out the form to the right to check out our data, and contact us to discuss your project or with any questions you may have at 1.877.CRIVER.1 (1.877.274.8371).